Ward, Richard A.

AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

Cross, D. A. E., Ashton, S. E., Ghiorghiu, S., Eberlein, C., Nebhan, C. A., Spitzler, P. J., Orme, J. P., Finlay, M. R. V., Ward, R. A., Mellor, M. J., et al. (2014) · Cancer Discovery

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 2,246

Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor

Finlay, M. R. V., Anderton, M., Ashton, S., Ballard, P., Bethel, P. A., Box, M. R., Bradbury, R. H., Brown, S. J., Butterworth, S., Campbell, A., et al. (2014) · Journal of Medicinal Chemistry

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 636

Structure-based design of targeted covalent inhibitors

Lonsdale, R., & Ward, R. A. (2018) · Chemical Society Reviews

Computational Drug Discovery MethodsClick Chemistry and Applications

Cited by 344

Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR)

Ward, R. A., Anderton, M. J., Ashton, S., Bethel, P. A., Box, M., Butterworth, S., Colclough, N., Chorley, C. G., Chuaqui, C., Cross, D. A. E., et al. (2013) · Journal of Medicinal Chemistry

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 279

Expanding the Armory: Predicting and Tuning Covalent Warhead Reactivity

Lonsdale, R., Burgess, J., Colclough, N., Davies, N. L., Lenz, E. M., Orton, A. L., & Ward, R. A. (2017) · Journal of Chemical Information and Modeling

Computational Drug Discovery MethodsClick Chemistry and Applications

Cited by 190

Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions

Floc'h, N., Martin, M. J., Riess, J. W., Orme, J. P., Staniszewska, A. D., Ménard, L., Cuomo, M. E., O'Neill, D. J., Ward, R. A., Finlay, M. R. V., et al. (2018) · Molecular Cancer Therapeutics

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 115

Exocytosis of Neutrophil Granule Subsets and Activation of Prolyl Isomerase 1 Are Required for Respiratory Burst Priming

McLeish, K. R., Uriarte, S. M., Tandon, S., Creed, T. M., Le, J., & Ward, R. A. (2013) · Journal of Innate Immunity

Neutrophil, Myeloperoxidase and Oxidative MechanismsCellular transport and secretion

Cited by 32

Antitumor activity of osimertinib in NSCLC harboring EGFR exon 20 insertions

Riess, J., Floch, N., Martin, M., Orme, J., Staniszewska, A., Menard, L., Cuomo, M. E., O'Neill, D., Ward, R., Finlay, R., et al. (2017) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 8